1. wolvergeek
2. jordanjames7
3. danielwilliamsms
4. dlrothwell
5. 7946manley049
1.danielwilliamsms 06/04/2018
Announces results from Phase 3 CheckMate -227
2.7946manley049 01/26/2018
$25 Million Payment
3.jordanjames7 01/26/2018
Crickets... Nobody?
4.7946manley049 01/29/2018
BMY Feb 62 calls are seeing interest with 6970 contracts trading
5.jordanjames7 01/22/2018
Product expansion
6.dlrothwell 02/05/2018
$BMY. news. - Announces that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survi…
7.wolvergeek 02/05/2018
Yes, by all means go down so I can buy more
8.dlrothwell 06/01/2018
Bristol-Myers Opdivo plus low-dose Vervoy
9.wolvergeek 04/17/2018
Bristol Myers Squibb (BMY) Will Face Significant Headwinds in 2019 - Here's Why
10.wolvergeek 04/17/2018
In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW